Hana Pharmaceutical Signs Exclusive Contract for New Drug Remimazolam in 6 Southeast Asian Countries
[Asia Economy Reporter Minwoo Lee] Hana Pharmaceutical announced on the 9th that it has acquired the exclusive contract rights for the new general anesthetic drug 'Remimazolam,' currently in preparation for launch, in six Southeast Asian countries (Vietnam, Indonesia, Thailand, the Philippines, Singapore, Malaysia) through a contract with PAION UK. The contract amount is 1.5 million euros (approximately 1.9 billion KRW).
Hot Picks Today
"Most Americans Didn't Want This"... Americans Lose 60 Trillion Won to Soaring Fuel Costs
- "Striking Will Lead to Regret": Hyundai-Kia Employees Speak Out... Uneasy Stares Toward Samsung Union
- Government Accelerates Expansion of Trade Network... All-Out Response to WTO Reform and EU Steel Regulations
- "If You Booked This Month, You Almost Lost Out... Why You Should Wait Until 'This Day' Before Paying for Flight Tickets"
- "Why Make Things Like This?" Foreign Media Highlights Bizarre Phenomenon Spreading in Korea
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
